Professor Gert Ossenkoppele was appointed as Professor of Hematology at the VU University Medical Center in Amsterdam, NL, in 2003. He obtained his doctorate in medicine at the same university in 1977. He has been board-certified in hematology and internal medicine since 1984. Prof. Ossenkoppele has authored over 400 publications in peer-reviewed journals and is an acclaimed speaker at many national and international scientific meetings. His research interests are mainly translational and include the stem cell biology of AML/myelodysplastic syndromes (MDS), leukemic stem cell target discovery, immunotherapy, and MRD detection using flow cytometry to inform treatment of AML/MDS.
Prof. Ossenkoppele is the principal investigator of national and international clinical trials in myeloid malignancies. He was previously a board member of the Dutch Society of Hematology. He is also an associate editor of HemaSphere, the official journal of the European Hematology Association (EHA), and the European Journal of Hematology, and is a regular reviewer for many other hematological journals (Blood, Leukemia, JCO, Haematologica, Oncotarget, NEJM). Prof. Ossenkoppele chairs the AML working party of HOVON (Dutch-Belgian Hematology Trial Group) and is a past vice-chair of the HOVON executive board. He currently chairs the Educational Committee of EHA, and is a lead participant of the AML work package of the European LeukemiaNet (ELN) as well as a board member of the ELN foundation.